Tetra Bio-Pharma (OTC: TBPMF) Provides Status of Its New Drug Submission Application in Canada
Reduvo™ would be Canada’s only DIN for a THC-based prescription drug The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / March 15, 2021 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) […]
